eXoZymes, Inc.
NASDAQ:EXOZBiotechnology
+$1.06 today
- Market cap
- $51.42M
- Beta
- 2.66
- P/E (TTM)
- -6.5
- EPS (TTM)
- -$1.14
Volume 0.01M
Average 0.01M
EXOZ Total Current Assets
All assets expected to be converted to cash or used up within one year.
eXoZymes, Inc.NASDAQ: EXOZ
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets falls 77.8% from a year ago
Total current assets stood at $2.09M at the end of Q1 FY2026, down 77.8% from a year earlier and down 46.9% from the prior quarter. Over 3 fiscal years it compounded at +38.9% a year.
Context
- Total current assets amounted to 52.0% of total assets at the end of Q1 FY2026, down 29.7 pp from a year earlier.
- Total current assets increased in 1 of the last 3 fiscal years.
What to watch
Whether total current assets keeps falling in the next quarterly balance sheet after a -77.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 3.94M USD
- Year-over-year change
- -63.6%
- 4-year CAGR
- +39.3%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.94M | -63.6% |
| FY2024 | 2024-12-31 | 10.82M | +791.6% |
| FY2023 | 2023-12-31 | 1.21M | -17.4% |
| FY2022 | 2022-12-31 | 1.47M | +40.4% |
| FY2021 | 2021-12-31 | 1.05M | — |
Total Current Assets vs competitors
How EXOZ compares with its peers on the latest reported figures
- Peers report in different currencies, so total current assets is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -77.8% is the lowest of 7, against a peer median of +10.7%.
- Total current assets amounts to 52.0% of total assets for EXOZ, versus a peer median of 94.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $188.3M USD | -14.1% | -10.8% | 93.9% | |
| Mar 2026 | $113.95M USD | +7.5% | +4.0% | 94.4% | |
| Mar 2026 | $35.81M USD | +56.6% | +0.2% | 99.1% | |
| Mar 2026 | $10.51M USD | +282.0% | — | 100.0% | |
| Dec 2025 | $8.55M USD | +13.9% | -29.4% | 74.4% | |
| Mar 2026 | CA$7.49M CAD | -59.5% | -35.9% | 91.7% | |
EXOZeXoZymes, Inc. | Mar 2026 | $2.09M USD | -77.8% | +38.9% | 52.0% |
| Peer median (excluding EXOZ) | — | +10.7% | -10.8% | 94.2% | |
Competitors are the stored peer set for EXOZ. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 547.81K | 558.57K | 66.53K | 9.72M | 3.04M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 468.35K | 809.53K | 882.32K | 737.28K | 517.36K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 30.19K | 101.14K | 264.76K | 363.79K | 382.89K |
| Total Current Assets | 1.05M | 1.47M | 1.21M | 10.82M | 3.94M |
| Property, Plant & Equipment (Net) | 1.3M | 1.22M | 2.34M | 2.21M | 2.21M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | (176.77K) |
| Total Non-current Assets | 1.3M | 1.22M | 2.34M | 2.21M | 2.03M |
| Total Assets | 2.35M | 2.69M | 3.56M | 13.03M | 5.97M |
| Account Payables | 267.3K | 385.8K | 702.91K | 924.25K | 1.24M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 63.56K | 42.27K | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 0 | 1M | 0 | 0 |
| Total Current Liabilities | 400.78K | 634.36K | 2.42M | 1.33M | 1.57M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 161.11K | 215K | 140.7K | 0 | 0 |
| Other Non-current Liabilities | 0 | 0 | 0 | 123.58K | 90.37K |
| Total Non-current Liabilities | 748.25K | 678.77K | 1.53M | 1.28M | 1.01M |
| Total Liabilities | 1.15M | 1.31M | 3.94M | 2.61M | 2.57M |
| Common Stock | 12 | 6 | 6 | 8 | 8 |
| Retained Earnings | (2.65M) | (4.05M) | (6.08M) | (11.95M) | (21.1M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 1.2M | 1.37M | (384.32K) | 10.42M | 3.4M |
| Total Debt | 720.63K | 608.77K | 1.61M | 1.39M | 1.24M |
| Net Debt | 172.82K | 50.2K | 1.55M | (8.33M) | (1.8M) |
eXoZymes, Inc.
NASDAQ:EXOZ
Intrinsic Alpha fair value
Locked
Current Price
$5.54
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.